Antitumor effects of bis(ethyl)polyamine analogs on mammary tumor development in FVB/NTgN (MMTVneu) transgenic mice

Neha Shah; Thomas Antony; Salim Haddad; Peter Amenta; Akira Shirahata; T. J. Thomas; Thresia Thomas

doi:10.1016/S0304-3835(99)00215-3

Antitumor effects of bis(ethyl)polyamine analogs on mammary tumor development in FVB/NTgN (MMTVneu) transgenic mice

Neha Shah, Thomas Antony, Salim Haddad, Peter Amenta, Akira Shirahata, T. J. Thomas, Thresia Thomas

Research output: Contribution to journal › Article › peer-review

15 Scopus citations

Abstract

We studied the therapeutic potential of two polyamine analogs on breast cancer using FVB/NTgN (MMTVneu), a transgenic mouse model with neu/erb-B2 oncogene overexpression. Treatment was initiated at 31 weeks of age with bis(ethyl)norspermine (BE333) and its higher homolog, BE3333 as i.p. injections once weekly. There was a 40% reduction in the average number of tumors per mouse in both treatment groups, by 10 weeks of treatment. BE3333-treated mice had 70-75% lower tumor volume than controls. Spermidine/spermine acetyl transferase activity was significantly higher in tumor tissues and kidneys of treated animals, whereas polyamine levels were lower than controls. Beneficial effects were also evident from the mortality rates in control and treatment groups. Our results suggest a potential use of selected bis(ethyl) polyamine analogs as antitumor agents in breast cancer. Copyright (C) 1999 Elsevier Science Ireland Ltd.

Original language	English (US)
Pages (from-to)	15-23
Number of pages	9
Journal	Cancer Letters
Volume	146
Issue number	1
DOIs	https://doi.org/10.1016/S0304-3835(99)00215-3
State	Published - Nov 1 1999
Externally published	Yes

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

Access to Document

10.1016/S0304-3835(99)00215-3

Cite this

@article{3fb4d01dc2f24bd7bf4cb1b1115ad741,

title = "Antitumor effects of bis(ethyl)polyamine analogs on mammary tumor development in FVB/NTgN (MMTVneu) transgenic mice",

abstract = "We studied the therapeutic potential of two polyamine analogs on breast cancer using FVB/NTgN (MMTVneu), a transgenic mouse model with neu/erb-B2 oncogene overexpression. Treatment was initiated at 31 weeks of age with bis(ethyl)norspermine (BE333) and its higher homolog, BE3333 as i.p. injections once weekly. There was a 40% reduction in the average number of tumors per mouse in both treatment groups, by 10 weeks of treatment. BE3333-treated mice had 70-75% lower tumor volume than controls. Spermidine/spermine acetyl transferase activity was significantly higher in tumor tissues and kidneys of treated animals, whereas polyamine levels were lower than controls. Beneficial effects were also evident from the mortality rates in control and treatment groups. Our results suggest a potential use of selected bis(ethyl) polyamine analogs as antitumor agents in breast cancer. Copyright (C) 1999 Elsevier Science Ireland Ltd.",

author = "Neha Shah and Thomas Antony and Salim Haddad and Peter Amenta and Akira Shirahata and Thomas, {T. J.} and Thresia Thomas",

year = "1999",

month = nov,

day = "1",

doi = "10.1016/S0304-3835(99)00215-3",

language = "English (US)",

volume = "146",

pages = "15--23",

journal = "Cancer Letters",

issn = "0304-3835",

publisher = "Elsevier Ireland Ltd",

number = "1",

}

TY - JOUR

T1 - Antitumor effects of bis(ethyl)polyamine analogs on mammary tumor development in FVB/NTgN (MMTVneu) transgenic mice

AU - Shah, Neha

AU - Antony, Thomas

AU - Haddad, Salim

AU - Amenta, Peter

AU - Shirahata, Akira

AU - Thomas, T. J.

AU - Thomas, Thresia

PY - 1999/11/1

Y1 - 1999/11/1

N2 - We studied the therapeutic potential of two polyamine analogs on breast cancer using FVB/NTgN (MMTVneu), a transgenic mouse model with neu/erb-B2 oncogene overexpression. Treatment was initiated at 31 weeks of age with bis(ethyl)norspermine (BE333) and its higher homolog, BE3333 as i.p. injections once weekly. There was a 40% reduction in the average number of tumors per mouse in both treatment groups, by 10 weeks of treatment. BE3333-treated mice had 70-75% lower tumor volume than controls. Spermidine/spermine acetyl transferase activity was significantly higher in tumor tissues and kidneys of treated animals, whereas polyamine levels were lower than controls. Beneficial effects were also evident from the mortality rates in control and treatment groups. Our results suggest a potential use of selected bis(ethyl) polyamine analogs as antitumor agents in breast cancer. Copyright (C) 1999 Elsevier Science Ireland Ltd.

AB - We studied the therapeutic potential of two polyamine analogs on breast cancer using FVB/NTgN (MMTVneu), a transgenic mouse model with neu/erb-B2 oncogene overexpression. Treatment was initiated at 31 weeks of age with bis(ethyl)norspermine (BE333) and its higher homolog, BE3333 as i.p. injections once weekly. There was a 40% reduction in the average number of tumors per mouse in both treatment groups, by 10 weeks of treatment. BE3333-treated mice had 70-75% lower tumor volume than controls. Spermidine/spermine acetyl transferase activity was significantly higher in tumor tissues and kidneys of treated animals, whereas polyamine levels were lower than controls. Beneficial effects were also evident from the mortality rates in control and treatment groups. Our results suggest a potential use of selected bis(ethyl) polyamine analogs as antitumor agents in breast cancer. Copyright (C) 1999 Elsevier Science Ireland Ltd.

UR - http://www.scopus.com/inward/record.url?scp=0032875359&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032875359&partnerID=8YFLogxK

U2 - 10.1016/S0304-3835(99)00215-3

DO - 10.1016/S0304-3835(99)00215-3

M3 - Article

C2 - 10656605

AN - SCOPUS:0032875359

SN - 0304-3835

VL - 146

SP - 15

EP - 23

JO - Cancer Letters

JF - Cancer Letters

IS - 1

ER -

Antitumor effects of bis(ethyl)polyamine analogs on mammary tumor development in FVB/NTgN (MMTVneu) transgenic mice

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this